Komori
Share Issuance and Disposal4888STELLA PHARMA CORPORATIONPharmaceuticals

Notice of Completion of Payment for New Shares and Stock Acquisition Rights through the First Third-Party Allotment under the Agreement Establishing the Share and Stock Acquisition Rights Issuance Program

Payment has been completed for 1,000,000 common shares and 10,500 stock acquisition rights through the third-party allotment to CVI Investments, Inc.

Worth reading
72In focus
Scored from 2 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
696000000
Japanese yen (proceeds from the issuance of common shares)
Wording
Definitive
How definitive the wording is.

Details of issuance or disposal

Issuance of new shares and stock acquisition rights through a third-party allotment

Who receives how much

New shares 1,000,000 common shares / Potential shares underlying the stock acquisition rights Up to 1,050,000 shares

CVI Investments, Inc.1,000,000 common shares and 10,500 stock acquisition rights (1,050,000 potential shares)

The lower thin line represents the existing number of shares to which these shares will be added.

New shares ¥696 per share / Stock Acquisition Rights ¥552 per stock acquisition right
Total issue value

New shares ¥696,000,000 / Stock Acquisition Rights ¥5,796,000

Amount of funds to be raised
Total payment amount ¥959,196,000 (¥5,796,000 from the issuance of stock acquisition rights and ¥953,400,000 from the exercise of stock acquisition rights) / Estimated net proceeds Not disclosed
Terms of the stock acquisition rights
Exercise price
Initial exercise price: ¥908 per share. Adjustment provisions and adjustment floor: Not disclosed
Exercise period
17 April 2026 to 16 April 2030
Number of Stock Acquisition Rights
Total number issued: 10,500; number of outstanding unexercised rights: Not disclosed
Payment date
16 April 2026
Most recent equity financing
The first third-party allotment announced in the "Notice Regarding Shelf Registration in Connection with the Execution of the Agreement Establishing the Share and Stock Acquisition Rights Issuance Program and the Issuance of New Shares and Stock Acquisition Rights through a Third-Party Allotment" dated 31 March 2026
Details of issuance or disposal
ItemDetails
Type of issuance or disposalIssuance of new shares and stock acquisition rights through a third-party allotment
Number of shares to be issued or disposed ofNew shares 1,000,000 common shares / Potential shares underlying the stock acquisition rights Up to 1,050,000 shares
Issue price and disposal priceNew shares ¥696 per share / Stock Acquisition Rights ¥552 per stock acquisition right
Total issue valueNew shares ¥696,000,000 / Stock Acquisition Rights ¥5,796,000
Amount of funds to be raisedTotal payment amount ¥959,196,000 (¥5,796,000 from the issuance of stock acquisition rights and ¥953,400,000 from the exercise of stock acquisition rights) / Estimated net proceeds Not disclosed
Payment date16 April 2026
Intended allotteeName CVI Investments, Inc. / Number of Shares 1,000,000 common shares and 10,500 stock acquisition rights (1,050,000 potential shares)
Exercise priceInitial exercise price: ¥908 per share. Adjustment provisions and adjustment floor: Not disclosed
Exercise period17 April 2026 to 16 April 2030
Number of Stock Acquisition RightsTotal number issued: 10,500; number of outstanding unexercised rights: Not disclosed
Most recent equity financingThe first third-party allotment announced in the "Notice Regarding Shelf Registration in Connection with the Execution of the Agreement Establishing the Share and Stock Acquisition Rights Issuance Program and the Issuance of New Shares and Stock Acquisition Rights through a Third-Party Allotment" dated 31 March 2026
Items this document does not state (17)
Estimated issuance expensesSpecific use of fundsIntended allottee's holding policyDilution RateTotal number of issued sharesBasis for determining the amount to be paidTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioProcedures under the Corporate Code of ConductMajor shareholders after the offeringImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The prescribed payment procedures for the first third-party allotment announced on 31 March 2026 have been completed.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice of Completion of Payment for New Shares and Stock Acquisition Rights through the First Third-Party Allotment under the Agreement Establishing the Share and Stock Acquisition Rights Issuance Program | STELLA PHARMA CORPORATION (4888) timely disclosure | Komori